PBQAX
Price
$28.11
Change
-$0.01 (-0.04%)
Updated
Jul 10 closing price
Net Assets
1.18B
RGAHX
Price
$84.98
Change
-$1.37 (-1.59%)
Updated
Jul 13 closing price
Net Assets
356.86B
Interact to see
Advertisement

PBQAX vs RGAHX

PBQAX vs RGAHX Comparison Chart in %
View a ticker or compare two or three
VS
PBQAX vs. RGAHX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBQAX is a StrongBuy and RGAHX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGAHX has more cash in the bank: 357B vs. PBQAX (1.18B). RGAHX pays higher dividends than PBQAX: RGAHX (0.40) vs PBQAX (0.04). PBQAX was incepted earlier than RGAHX: PBQAX (36 years) vs RGAHX (11 years). PBQAX (0.91) is less costly to investors than RGAHX (0.44). PBQAX is a more actively managed with annual turnover of: 59.00 vs. RGAHX (32.00). RGAHX has a lower initial minimum investment than PBQAX: RGAHX (250) vs PBQAX (1000). PBQAX annual gain was more profitable for investors over the last year : 12.94 vs. RGAHX (4.43). RGAHX return over 5 years is better than : 16.49 vs. PBQAX (3.55).
PBQAXRGAHXPBQAX / RGAHX
Total Expense Ratio0.910.44207%
Annual Report Gross Expense Ratio0.910.44207%
Fund Existence36 years11 years-
Gain YTD13.8067.244191%
Front Load6%N/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets1.18B357B0%
Annual Yield % from dividends0.040.409%
Returns for 1 year12.944.43292%
Returns for 3 years32.5739.8882%
Returns for 5 years3.5516.4922%
Returns for 10 years52.28102.8451%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSEIX63.23N/A
N/A
Nuveen Mid Cap Value Opportunities I
FIKCX72.53N/A
N/A
Fidelity Advisor Health Care Z
VADGX32.27N/A
N/A
Vanguard Advice Select Dividend Gr Admrl
FBPGX29.15N/A
N/A
Cantor Fitzgerald Equity Dividend Plus A
PAMCX94.34N/A
N/A
T. Rowe Price Mid-Cap Growth Adv